A breast cancer diagnosis should never amount to a death sentence simply because a patient lives far from a hospital, cannot afford diagnostic tests, or lacks access to treatment. Yet these obstacles remain widespread across low- and middle-income countries (LMICs), where health systems operate under constrained resources and persistent shortages of medical professionals.

The stakes are captured in World Health Organization (WHO) data: approximately 70% of breast cancer deaths worldwide in 2024 occurred in LMICs. WHO estimates likewise expose a stark survival divide, with median five-year survival at 41.9% in low-income countries versus 87.3% in high-income countries. Globally, breast cancer is the most commonly diagnosed cancer among women: WHO recorded 2.3 million new cases and roughly 670,000 deaths from the disease in 2022.

As Breast Cancer Awareness Month draws to a close, initiatives in Mexico, Rwanda, and Peru show how innovations in healthcare delivery can bring timely diagnosis and treatment closer to patients. The broader backdrop is WHO's Global Breast Cancer Initiative, launched in 2021, which aims to reduce global breast cancer mortality by 2.5% per year — a pace the agency estimates could avert roughly 2.5 million deaths by 2040.

In Mexico, breast cancer is the leading cause of cancer-related death among women, claiming roughly one life every hour. In October 2025, the government launched its Universal Care Model for Breast Cancer, a national strategy designed to guarantee timely detection, diagnosis, and continuous treatment regardless of a patient's health insurance status.

The model prioritizes public education, early detection, infrastructure expansion, comprehensive diagnosis, and continuity of care. It promotes breast health awareness from age 20 and biennial mammography for women aged 40 and older, while setting explicit targets: diagnostic procedures completed within 30 days of a suspected cancer, and treatment initiated within 21 days of diagnosis.

To expand capacity, Mexico plans to acquire 1,000 mammography units and 1,000 ultrasound machines — potentially lifting national throughput to approximately 8.9 million mammograms annually — and to establish 20 additional diagnostic centers staffed by specialized imaging and pathology personnel.

Notably, the strategy reaches beyond screening equipment. By fixing timelines from suspicion through treatment, it aims to reduce the uncertainty and delays that allow potentially treatable cancers to progress. How quickly the procurement plans and the 20 new diagnostic centers move from announcement to operation will be a key marker of whether the model delivers on its timelines.

Rwanda has taken a different route to addressing shortages of specialized health workers. With many patients diagnosed at advanced stages, the country has adopted task-sharing, in which trained nurses and midwives conduct breast health assessments and clinical examinations and refer women for further diagnosis.

Rwanda's Ministry of Health, working with nongovernment organizations and academic institutions, has supported community-based services that bring breast health education and early detection closer to underserved women.

Task-sharing — endorsed by the WHO when paired with appropriate training and supervision — redistributes selected responsibilities across the healthcare workforce. Clinical breast examinations cannot replace imaging or tissue biopsy, but they can flag suspicious symptoms and trigger referrals where specialists are scarce. For women living far from cancer centers, a trusted local health worker is often the first point of contact. Community-level detection, however, must be linked to timely diagnostic confirmation and treatment; otherwise, the burden of navigating the health system still falls on the patient.

Peru offers a third lesson: dismantling financial, legal, and practical barriers to care. Its National Cancer Law of 2021 established a framework for universal, free, and comprehensive cancer services.

Under Law No. 31561, enacted in 2022, female employees in both the public and private sectors are entitled to one paid, non-compensable day of leave each year for breast and cervical cancer screening. The measure recognizes that access depends not only on whether services exist, but on whether women can take time away from work.

Peru has also pursued risk-based breast cancer detection, including enhanced surveillance for women with hereditary predispositions or other significant risk factors. Decentralization efforts have combined training for healthcare professionals in breast examinations and diagnostic procedures with patient navigation initiatives that help women complete referrals and stay in treatment.

For the Philippines, an archipelago of more than 7,000 islands, these experiences offer practical guidance. The National Integrated Cancer Control Act (NICCA) of 2019 already provides a framework spanning cancer prevention, screening, diagnosis, treatment, survivorship, and supportive care; the challenge is turning its commitments into dependable services nationwide.

Each country underscores a distinct lever: Mexico highlights the value of sustained financing, diagnostic capacity, and measurable treatment timelines; Rwanda demonstrates how trained primary healthcare workers can extend services into communities; and Peru shows how workplace protections and patient navigation can reduce barriers to care.

These lessons carry particular weight where geography and household expenses complicate access to care. Innovative cancer medicines and diagnostic technologies remain essential — but so are innovations in healthcare delivery that allow patients to actually benefit from them.

Ultimately, progress should be measured not merely by facilities established, screening tests performed, or policies enacted, but by how many women receive timely, appropriate treatment — and survive.

Teodoro B. Padilla is executive director of the Pharmaceutical and Healthcare Association of the Philippines, which represents the biopharmaceutical medicines and vaccines industry in the country. Its members are at the forefront of developing, investing in, and delivering innovative medicines, vaccines, and diagnostics that help Filipinos live healthier, more productive lives.